Aptevo Therapeutics Inc. — Major Shareholding Notification 2016

Aug 3, 2016

SC 13G 1 aptevo_13g.htm SC 13G Field: Rule-Page

Field: /Rule-Page

| UNITED
STATES | |
| --- | --- |
| SECURITIES
AND EXCHANGE COMMISSION | |
| Washington,
D.C. 20549 | |
| SCHEDULE
13G | |
| Under
the Securities Exchange Act of 1934 | |
| (Amendment
No. ) | |
| Aptevo
Therapeutics Inc. | |
| (Name
of Issuer) | |
| Common
Stock, par value $0.001 | |
| (Title
of Class of Securities) | |
| 03835L108 | |
| (CUSIP
Number) | |
| Carl
A Valenstein, Esq. Morgan,
Lewis & Bockius LLP One Federal
Street Boston,
MA 02110 (617)
341-7400 | |
| August
1, 2016 | |
| (Date
of Event Which Requires Filing of this Statement) | |
| Check
the appropriate box to designate the rule pursuant to which this Schedule is filed: | |
| o | Rule 13d-1(b) |
| o | Rule 13d-1(c) |
| x | Rule 13d-1(d) |
| The
remainder of this cover page shall be filled out for a reporting person’s initial
filing on this form with respect to the subject class of securities, and for any subsequent
amendment containing information which would alter the disclosures provided in a prior
cover page. The
information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section
18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the Notes). | |

Field: Rule-Page

Field: /Rule-Page Field: Page; Sequence: 1

Field: /Page

CUSIP No. 03835L108 13G Page 2 of 5

| 1. — 2. | Names
Of Reporting Persons I.R.S.
Identification No. Of Above Persons (Entities Only) Intervac,
l.l.c. — check
the appropriate box if a group | | (a) o (b) x |
| --- | --- | --- | --- |
| 3. | sec
use only | | |
| 4. | citizenship
or place of organization Maryland | | |
| number
of shares beneficially owned by each reporting person with: | 5. | sole
voting power | 2,172,125 |
| | 6. | shared
voting power | 0 |
| | 7. | sole
dispositive power | 2,172,125 |
| | 8. | shared
dispositive power | 0 |
| 9. | aggregate
amount beneficially owned by each reporting person | | 2,172,125 1 |
| 10. | check
box if the aggregate amount in row (9) excludes certain shares (See Instructions) x | | |
| 11. | percent
of class represented by amount in row (9) | | 10.7% |
| 12. | type
of reporting person (See Instructions) | | IN |

Field: Rule-Page

Field: /Rule-Page

1 The Reporting Person received 2,172,125 shares of the Issuer’s common stock as a result of a spin-off of the Issuer from Emergent BioSolutions Inc., effective August 1, 2016.

Field: Rule-Page

Field: /Rule-Page Field: Page; Sequence: 2

Field: /Page

CUSIP No. 03835L108 13G Page 3 of 5

Item 1.
(a) Name of Issuer:	Aptevo Therapeutics Inc.
(b) Address of Issuer’s Principal Executive Offices:	2401 4th Ave., Suite
1050
	Seattle, Washington 98121
Item 2.
(a) Name of Person Filing:	Intervac, L.L.C.
(b) Address of Principal
Business	c/o Harry Bauer
Office or, if none, Residence:	16027 Comprint Circle
	Gaithersburg, MD 20877-1316
(c) Citizenship:	Intervac, L.L.C. is a Maryland limited liability company
(d) Title of Class of
Securities:	Common Stock, par value $0.001 per share
(e) CUSIP Number:	03835L108

Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 13d-2(b) or (c), check whether the person filing is a:

| (a) | o | Broker or dealer registered
under section 15 of the Act (15 U.S.C. 78o). |
| --- | --- | --- |
| (b) | o | Bank as defined in section 3(a)(6) of the
Act (15 U.S.C. 78c). |
| (c) | o | Insurance company as defined in section
3(a)(19) of the Act (15 U.S.C. 78c). |
| (d) | o | Investment company registered under section
8 of the Investment Company Act of 1940 (15 U.S.C 80a-8). |
| (e) | o | An investment adviser in accordance with
§240.13d-1(b)(1)(ii)(E); |
| (f) | o | An employee benefit plan or endowment fund
in accordance with §240.13d-1(b)(1)(ii)(F); |
| (g) | o | A parent holding company or control person
in accordance with § 13d-1(b)(1)(ii)(G); |
| (h) | o | A savings associations as defined in Section
3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); |
| (i) | o | A church plan that is excluded from the
definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15U.S.C. 80a-3); |
| (j) | o | Group, in accordance with §240.13d-1(b)(1)(ii)(J). |

Field: Rule-Page

Field: /Rule-Page Field: Page; Sequence: 3

Field: /Page

CUSIP No. 03835L108 13G Page 4 of 5

Item 4. Ownership.

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

| Amount beneficially
owned: — Percent of
class: | 10.74% | |
| --- | --- | --- |
| | Calculation of percentage of
beneficial ownership is based on 20,229,849 shares of the Issuer’s common stock outstanding as of August 1, 2016. | |
| (c) | Number of
shares as to which the person has: | |
| | Sole power
to vote or to direct the vote: | 2,172,125 |
| | Shared power
to vote or to direct the vote: | 0 |
| | Sole power
to dispose or to direct the disposition of: | 2,172,125 |
| | Shared power
to dispose or to direct the disposition of: | 0 |

Item 5 Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following o .

Items 6 – 10 Not Applicable

Field: Rule-Page

Field: /Rule-Page Field: Page; Sequence: 4

Field: /Page

CUSIP No. 03835L108 13G Page 5 of 5

Field: Rule-Page

Field: /Rule-Page

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

August 2, 2016
Date
INTERVAC, L.L.C.
/s/ Harry Bauer, its General Manager
Signature

Field: Rule-Page

Field: /Rule-Page